Investigating the effect of nanocurcumin on patients with Alzheimer’s disease

INTERVENTION: Intervention 1: Intervention group: patients with Alzheimer’s disease who will receive nanocurcumin soft gel (exirnanosina pharmaceutical company)at a dose of 40 mg per day for si Xmonths. Intervention 2: Control group: patients with Alzheimer’s disease who will receive one soft gel of placebo per (similar to nanucorcumin in shape, size and color ) per day for si Xmonths. CONDITION: Alzheimer’s disease. ; Alzheimers disease, unspecified G30.9 PRIMARY OUTCOME: Brain volume. Timepoint: Beginning of the study and after 6 months of intervention. Method of measurement: 1.5Tesla structural MRI. Cognitive function. Timepoint: At the beginning of study and after 6 months of intervention. Method of measurement: Montreal Cognitive Assessment (MoCA) test. SECONDARY OUTCOME: Demographic factor(age). Timepoint: At the beginning of study. Method of measurement: Based on date of birth. Gender. Timepoint: At the beginning of study. Method of measurement: Inquiring about gender. INCLUSION CRITERIA: Patients diagnosed with mild or moderate Alzheimer’s disease based on DSM‐5 and NIA‐AA 50‐85 years old patients Ability to do cognitive tests and MRI